Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471952 · ClinicalTrials.gov registry record · Phase 3
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
A Phase 3 study of Migraine With Aura and Migraine Without Aura, sponsored by Diamond Headache Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00471952: Completed Phase 3 study of Migraine With Aura and Migraine Without Aura, sponsored by Diamond Headache Clinic.
NCT00471952 is a Phase 3 study of Migraine With Aura and Migraine Without Aura that has completed, run by Diamond Headache Clinic. The registered enrollment target is 50 participants, below the 167-participant average among 6 other Migraine With Aura trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00471952, a Phase 3 study of Migraine With Aura and Migraine Without Aura, has completed, sponsored by Diamond Headache Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.
Conditions Studied
Interventions
- DRUG Maxalt 10mg MLT plus Caffeine 75mg
- DRUG Maxalt 10mg MLT plus Placebo
- DRUG Placebo + Placebo
Study Locations (1)
Illinois
- Diamond Headache Clinic - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
What the finished NCT00471952 record still lists
NCT00471952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 167-participant average among 6 other Migraine With Aura trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Migraine With Aura appearing as the primary indexed condition, and to 3 interventions - of which Maxalt 10mg MLT plus Caffeine 75mg is the first listed.
NCT00471952 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00471952 about?
NCT00471952 is a clinical study titled "Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache". The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication lab...
What is the current status of trial NCT00471952?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2007-04. Estimated completion is 2008-04.
What conditions does trial NCT00471952 study?
This clinical trial studies the following conditions: Migraine With Aura, Migraine Without Aura.
What interventions are being tested in trial NCT00471952?
The interventions under investigation include: Maxalt 10mg MLT plus Caffeine 75mg (DRUG), Maxalt 10mg MLT plus Placebo (DRUG), Placebo + Placebo (DRUG).
Who is sponsoring clinical trial NCT00471952?
This trial is sponsored by Diamond Headache Clinic, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00471952 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine With Aura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
COMPLETED · Phase 3
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
-
Integrative Migraine Pain Alleviation Through Chiropractic Therapy
COMPLETED · NA
-
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
COMPLETED
-
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia